Recon: Moderna launches Phase 3 COVID-19 vaccine testing; AstraZeneca, Daiichi sign $6B deal for targeted cancer drug

• Trump signs orders aimed at lowering drug prices in largely symbolic move (Washington Post) (STAT) (NYTimes) (Reuters)
• Meadows says White House is 'hopeful' it can announce new coronavirus therapies 'in the coming days' (The Hill)
• Gilead's second act in cell therapy gets its first approval (BioPharmaDive) (Endpoints) (FDA)
• Moderna gets further $472 million U.S. award for coronavirus vaccine development (Reuters)
• Moderna's COVID-19 vaccine candidate moves into late-stage trial (Reuters) (WSJ) (FT)
• Indivior to pay $600 million to settle U.S. opioid treatment marketing claims (Reuters) (FT) (DOJ)
• Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine (Reuters)
• Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine (NYTimes)
• FDA demands more data from Solid Bio to lift gene therapy hold (Fierce) (Endpoints)
• U.S. Republicans to unveil coronavirus aid proposal as time runs out on jobless benefits (Reuters)

• Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags – sources (Reuters)
• AstraZeneca Strikes $6 Billion Cancer Drug Deal (WSJ) (Reuters) (Press)
• Novartis, Austria team up to support Tyrol antibiotics plant (Reuters) (Press)
• Diagnostics group Novacyt to launch more COVID-19 testing products (Reuters)
• Biocad discussing potential COVID-19 vaccine production in China (Reuters)
• India to boost drug and medical device production to lessen reliance on imports (Reuters)
• World Hepatitis Day: fast-tracking the elimination of hepatitis B among mothers and children (WHO)

• The World’s Supply Chain Isn’t Ready for a Covid-19 Vaccine (Bloomberg)
• US ‘failures’ are holding back search for coronavirus drugs (The Guardian)
• The Color of COVID: Will Vaccine Trials Reflect America’s Diversity? (KHN)
• A Possible Weapon Against the Pandemic: Printing Human Tissue (NYTimes)
• Covid-19 infections leave an impact on the heart, raising concerns about lasting damage (STAT)
• Human clinical trials of COVID-19 vaccine 'Covaxin' begin at a hospital in Odisha (Economic Times)
• Testing Results Take Too Long, U.S. Official Concedes (NYTimes)
• FDA authorizes first COVID-19 test for screening people without symptoms (Fierce) (FDA)
• Coronavirus (COVID-19) Update: Daily Roundup July 24, 2020 (FDA)

• The top 20 drugs by global sales in 2019 (Fierce)
• A Boy With Muscular Dystrophy Was Headed For A Wheelchair. Then Gene Therapy Arrived (NPR)
• Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb (Endpoints)
• Boehringer Ingelheim beefs up vet portfolio with GST buyout; Novartis, Austria to invest €150M in European manufacturing deal (Endpoints)
• Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK (Endpoints)
• TCR² releases early data from some PhI patients, sparking optimism from analysts (Endpoints)
• Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease (Endpoints)
• Sobi To Appeal Against EMA Rejection For Emapalumab (Pink Sheet)

• Israel's Zebra Medical gets FDA clearance for mammography tool (Reuters)
• Abbott receives FDA approval for neurostimulator-controlling iPhone app for personalizing therapies for pain, Parkinson's disease (Fierce)
• Want To Make Faster Class I Recall Decisions? Then Put Women In The Boardroom, Study Says (MedtechInsight)
• Edwards aims for 5% TAVR sales growth in 2020 after seeing demand bounce back (MedtechDive)
• Reshaping Medtech Regulations After A Health Care Emergency: What COVID-19 Could Mean For The UK (MedtechInsight)

• Regulatory considerations on the classification of non-medical masks or face coverings: Notice to industry (Health Canada)
• Coronavirus Q&A: Sidley Austin's FDA Group Leader (Law360)
• Generic group fails again to block California law that bans pay-to-delay deals (STAT) (Law360)
• AbbVie Sues To Block Dr. Reddy's Generic Leukemia Drug (Law360)
• Why A Surge In Drug Pricing Litigation Is Unlikely (Law360)
• Judge Advises Freeing Amgen, Teva From Suits Over Sensipar (Law360)